Shiga Toxin 2 Triggers C3a-Dependent Glomerular and Tubular Injury through Mitochondrial Dysfunction in Hemolytic Uremic Syndrome

Shiga toxin (Stx)-producing Escherichia coli is the predominant offending agent of post-diarrheal hemolytic uremic syndrome (HUS), a rare disorder of microvascular thrombosis and acute kidney injury possibly leading to long-term renal sequelae. We previously showed that C3a has a critical role in the development of glomerular damage in experimental HUS. Based on the evidence that activation of C3a/C3a receptor (C3aR) signaling induces mitochondrial dysregulation and cell injury, here we investigated whether C3a caused podocyte and tubular injury through induction of mitochondrial dysfunction in a mouse model of HUS. Mice coinjected with Stx2/LPS exhibited glomerular podocyte and tubular C3 deposits and C3aR overexpression associated with cell damage, which were limited by C3aR antagonist treatment. C3a promoted renal injury by affecting mitochondrial wellness as demonstrated by data showing that C3aR blockade reduced mitochondrial ultrastructural abnormalities and preserved mitochondrial mass and energy production. In cultured podocytes and tubular cells, C3a caused altered mitochondrial fragmentation and distribution, and reduced anti-oxidant SOD2 activity. Stx2 potentiated the responsiveness of renal cells to the detrimental effects of C3a through increased C3aR protein expression. These results indicate that C3aR may represent a novel target in Stx-associated HUS for the preservation of renal cell integrity through the maintenance of mitochondrial function.

[1]  J. Thurman,et al.  Complement Activation Fragments Are Increased in Critically Ill Pediatric Patients with Severe AKI , 2021, Kidney360.

[2]  Yafeng Li,et al.  Mitochondrial Reactive Oxygen Species and Their Contribution in Chronic Kidney Disease Progression Through Oxidative Stress , 2021, Frontiers in Physiology.

[3]  G. Beeson,et al.  Mitochondrial C3a Receptor Activation in Oxidatively Stressed Epithelial Cells Reduces Mitochondrial Respiration and Metabolism , 2021, Frontiers in Immunology.

[4]  K. Überla,et al.  Complement Activation in Kidneys of Patients With COVID-19 , 2021, Frontiers in Immunology.

[5]  G. Remuzzi,et al.  C3a receptor blockade protects podocytes from injury in diabetic nephropathy. , 2020, JCI insight.

[6]  D. McAllister,et al.  Shiga-Toxin E. coli Hemolytic Uremic Syndrome: Review of Management and Long-term Outcome , 2020, Current Pediatrics Reports.

[7]  L. Johannes,et al.  Shiga toxin signals via ATP and its effect is blocked by purinergic receptor antagonism , 2019, Scientific Reports.

[8]  E. Porcellini,et al.  The structure of the Shiga toxin 2a A‐subunit dictates the interactions of the toxin with blood components , 2019, Cellular microbiology.

[9]  G. Remuzzi,et al.  Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome , 2019, Microorganisms.

[10]  D. Müller,et al.  Short- and Long-Term Renal Outcome of Hemolytic-Uremic Syndrome in Childhood , 2018, Front. Pediatr..

[11]  F. Gunzer,et al.  Modeling Hemolytic-Uremic Syndrome: In-Depth Characterization of Distinct Murine Models Reflecting Different Features of Human Disease , 2018, Front. Immunol..

[12]  R. Branicky,et al.  Superoxide dismutases: Dual roles in controlling ROS damage and regulating ROS signaling , 2018, The Journal of cell biology.

[13]  E. Holzbaur,et al.  Mitochondrial-cytoskeletal interactions: dynamic associations that facilitate network function and remodeling. , 2018, Current opinion in physiology.

[14]  M. Morigi,et al.  Shiga toxin triggers endothelial and podocyte injury: the role of complement activation , 2019, Pediatric Nephrology.

[15]  J. Vande Walle,et al.  Is eculizumab efficacious in Shigatoxin-associated hemolytic uremic syndrome? A narrative review of current evidence , 2018, European Journal of Pediatrics.

[16]  G. Remuzzi,et al.  Human mesenchymal stromal cells transplanted into mice stimulate renal tubular cells and enhance mitochondrial function , 2017, Nature Communications.

[17]  S. Loos,et al.  Haemolytic uraemic syndrome , 2017, Journal of internal medicine.

[18]  L. Pape,et al.  Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement , 2015, Medicine.

[19]  C. Rylander,et al.  Shiga Toxin–Induced Complement-Mediated Hemolysis and Release of Complement-Coated Red Blood Cell–Derived Microvesicles in Hemolytic Uremic Syndrome , 2015, The Journal of Immunology.

[20]  G. Remuzzi,et al.  Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement. , 2014, Journal of the American Society of Nephrology : JASN.

[21]  N. Gretz,et al.  Direct acute tubular damage contributes to Shigatoxin-mediated kidney failure , 2014, The Journal of pathology.

[22]  M. Pepys,et al.  Protection of Human Podocytes from Shiga Toxin 2-Induced Phosphorylation of Mitogen-Activated Protein Kinases and Apoptosis by Human Serum Amyloid P Component , 2014, Infection and Immunity.

[23]  E. Christensen,et al.  Megalin in acute kidney injury: foe and friend. , 2014, American journal of physiology. Renal physiology.

[24]  J. Köhl,et al.  C3a modulates IL-1β secretion in human monocytes by regulating ATP efflux and subsequent NLRP3 inflammasome activation. , 2013, Blood.

[25]  J. Henderson,et al.  Distinct renal pathology and a chemotactic phenotype after enterohemorrhagic Escherichia coli shiga toxins in non-human primate models of hemolytic uremic syndrome. , 2013, The American journal of pathology.

[26]  K. Sinha,et al.  Oxidative stress: the mitochondria-dependent and mitochondria-independent pathways of apoptosis , 2013, Archives of Toxicology.

[27]  Lawrence Copelovitch,et al.  Long-term outcomes of Shiga toxin hemolytic uremic syndrome , 2013, Pediatric Nephrology.

[28]  G. Remuzzi,et al.  Thrombotic microangiopathy: E. coli O104:H4 German outbreak: a missed opportunity , 2012, Nature Reviews Nephrology.

[29]  Ulrich C. Klostermeier,et al.  Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study , 2012, BMJ : British Medical Journal.

[30]  G. Lombardi,et al.  Functional modulation of human monocytes derived DCs by anaphylatoxins C3a and C5a , 2012, Immunobiology.

[31]  G. Remuzzi,et al.  Alternative Pathway Activation of Complement by Shiga Toxin Promotes Exuberant C3a Formation That Triggers Microvascular Thrombosis , 2011, The Journal of Immunology.

[32]  D. Karpman,et al.  Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. , 2011, Blood.

[33]  J. Avorn.  Eculizumab in Severe Shiga-Toxin-Associated HUS , 2011 .

[34]  J. Thurman,et al.  Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[35]  A. Kelly,et al.  Cyclic AMP plays a critical role in C3a-receptor-mediated regulation of dendritic cells in antigen uptake and T-cell stimulation. , 2008, Blood.

[36]  J. Lambris,et al.  C3a Is Required for the Production of CXC Chemokines by Tubular Epithelial Cells after Renal Ishemia/Reperfusion1 , 2007, The Journal of Immunology.

[37]  J. Lambris,et al.  C 3 a Is Required for the Production of CXC Chemokines by Tubular Epithelial Cells after Renal Ishemia / Reperfusion 1 , 2007 .

[38]  G. Remuzzi,et al.  Shigatoxin-induced endothelin-1 expression in cultured podocytes autocrinally mediates actin remodeling. , 2006, The American journal of pathology.

[39]  V. Shoshan-Barmatz,et al.  The expression level of the voltage-dependent anion channel controls life and death of the cell. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Thurman,et al.  Acute tubular necrosis is characterized by activation of the alternative pathway of complement. , 2005, Kidney international.

[41]  F. Gunzer,et al.  Molecular and functional analysis of Shiga toxin-induced response patterns in human vascular endothelial cells. , 2003, Blood.

[42]  G. Remuzzi,et al.  Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1. , 2002, Kidney international.

[43]  P. Stricklett,et al.  Molecular basis for high renal cell sensitivity to the cytotoxic effects of shigatoxin-1: upregulation of globotriaosylceramide expression. , 2002, Journal of the American Society of Nephrology : JASN.

[44]  R. Discipio,et al.  Complement C3a and C5a Induce Different Signal Transduction Cascades in Endothelial Cells1 , 2002, The Journal of Immunology.

[45]  J. di Rago,et al.  The ATP synthase is involved in generating mitochondrial cristae morphology , 2002, The EMBO journal.

[46]  T. Pysher,et al.  Response to single and divided doses of Shiga toxin-1 in a primate model of hemolytic uremic syndrome. , 2001, Journal of the American Society of Nephrology : JASN.

[47]  M. Walport.  Complement. First of two parts. , 2001, The New England journal of medicine.

[48]  P. Stricklett,et al.  Cytotoxic effect of Shiga toxin-1 on human glomerular epithelial cells. , 2000, Kidney international.

[49]  T. Pysher,et al.  Characterization of the baboon responses to Shiga-like toxin: descriptive study of a new primate model of toxic responses to Stx-1. , 1999, The American journal of pathology.

[50]  P. Stricklett,et al.  Shiga toxin-1 regulation of cytokine production by human proximal tubule cells. , 1998, Kidney international.

[51]  B. Kaplan.  Shiga toxin-induced tubular injury in hemolytic uremic syndrome. , 1998, Kidney international.

[52]  S. Adler,et al.  Glomerular Endothelial Cell Injury Mediated by Shiga-Like Toxin-1 , 1998, Kidney and Blood Pressure Research.

[53]  A. Caprioli,et al.  Apoptosis of Renal Cortical Cells in the Hemolytic-Uremic Syndrome: In Vivo and In Vitro Studies , 1998, Infection and Immunity.

[54]  G. Remuzzi,et al.  Verotoxin-1 promotes leukocyte adhesion to cultured endothelial cells under physiologic flow conditions. , 1995, Blood.

[55]  G. Fick,et al.  Hypocomplementemia and leukocytosis in diarrhea-associated hemolytic uremic syndrome. , 1992, Nephron.

[56]  R. Gilman,et al.  Renal histopathology in the hemolytic-uremic syndrome following shigellosis. , 1984, Clinical nephrology.

[57]  J. Ortuño,et al.  Hemolytic uremic syndrome with hypocomplementemia and deposits of IgM and C3 in the involved renal tissue. , 1981, Clinical nephrology.

[58]  P. Lambert,et al.  The complement system in hemolytic-uremic syndrome in childhood. , 1980, Clinical nephrology.

[59]  H. Tiddens,et al.  Haemolytic uraemic syndrome. , 1979, Paediatrician.

[60]  P. Raghupathy,et al.  Haemolytic-uraemic syndrome complicating shigella dystentery in south Indian children. , 1978, British medical journal.

[61]  R. Laguens,et al.  Persistent glomerulonephritis following the haemolytic-uremic syndrome. Immunopathological and morphological studies. , 1977, Clinical and experimental immunology.

[62]  S. Cutillo.  [Hemolytic-uremic syndrome]. , 1973, La Pediatria.

[63]  E. Weibel,et al.  PRACTICAL STEREOLOGICAL METHODS FOR MORPHOMETRIC CYTOLOGY , 1966, The Journal of cell biology.

[64]  J. Wágner.  Acute tubular necrosis with anaemia. , 1954, Great Ormond Street journal.